Table 1.
Patient Demographics
| Variable | Nonsmokers | SPS Group | GOLD Stage Group |
SPIROMICS Cohorta | ||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| No. of patients | 77 | 341 | 178 | 303 | 81 | 2,973 |
| Age, y | 55.4 ± 10.2 | 59.6 ± 9.5 | 66.4 ± 8.4 | 64.9 ± 7.8 | 64.8 ± 8.3 | 63.0 ± 9.2 |
| Male sex | 45 | 56 | 68 | 64 | 57 | 53 |
| White race | 66 | 62 | 81 | 85 | 77 | 78 |
| FEV1 % predicted | 102.9 ± 12.1 | 98.4 ± 14.0 | 92.6 ± 10.3 | 67.0 ± 8.7 | 44.0 ± 4.3 | 75.0 ± 26.7 |
| FEV1 to FVC % ratio predicted | 103.5 ± 5.2 | 100 ± 6.1 | 83.9 ± 7.0 | 73.5 ± 10.8 | 55.5 ± 11.7 | 80.0 ± 21.4 |
| Current smoker | 0 | 56 | 35 | 40 | 38 | 37 |
| Chronic bronchitis | 5 | 42 | 36 | 54 | 53 | 42 |
Data are presented as percentage or mean ± SD, unless otherwise indicated. GOLD = Global Initiative on Chronic Obstructive Lung Disease; SPIROMICS = Subpopulations and Intermediate Outcome Measures in COPD Study; SPS = smokers with preserved spirometry.
a
Baseline characteristics of full SPIROMICS cohort at the time of the study.